The Baker Bro's. know a discount price when they see one.
This, from a S.A. article today: "Felix Baker purchased 103,167 shares on November 14 and 823,772 shares on November 9-13 by his funds", right about this price range. I'm assuming these are open market purchases.
I'm certain this co. will be sold in due time, and the p.p.s., given the low float, could easily be in the $50. range, or a lot more with greater global penetration. Once the Onco Dx for prostate cancer gets traction, which probably won't come until Q-4 of of 2013, the earnings will really ramp up, along with the share price. European sales are getting good traction and will further drive value. Forget about the regular 10% fluctuation in share price. It's a low float stock, and you have to expect that from same.
This 10% fluctuation has been more than 20- ) but I have bought more with each of these take downs.
jmho - but Genomic Health will be taken out before the Oco Dx for Prostate takes off because a buyer knows that will increase the takeover price considerably.
Steve Burrill is in Geneva and the outside the US operations are the under appreciated aspect of the company ...say nothing of the research arm headed by Baker.